Managing treatment resistant depression: what do the guidelines say?

Author/s
Maria Antonietta Nettis, Carmine M. Pariante
Citation
Issue 5 Winter 2018
CEPiP.2018.1.120-125
https://doi.org/10.65031/piag8006
Abstract

Numerous approaches have been used to define and stage treatment-resistant depression (TRD) as well as to find predictors of treatment outcome. Nevertheless, TRD remains a complex disorder, with high morbidity and mortality. This paper briefly reviews current guidelines for managing TRD, summarising the best pharmacological strategies and ‘next steps’ of psychological and physical treatments. When depressed patients fail to remit after two or more conventional antidepressant treatments, combined approaches, targeting multiple molecular, psychological and physical mechanisms, seem to be the most effective strategy.

Keywords
Treatment-resistant depression, antidepressants, combined approaches, somatic therapies, predictors
References
  1. Anderson IM. Drug treatment of depression: reflections on the evidence. Advances in Psychiatric Treatment. 2003 Jan;9(1):11-20. https://doi.org/10.1192/apt.9.1.11
  2. McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, Barakat M, Miguelez M. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders. 2014 Mar 1;156:1-7. https://doi.org/10.1016/j.jad.2013.10.043
  3. Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. The Journal of Clinical Psychiatry. 2009 Feb;70(2):177-84. https://doi.org/10.4088/jcp.08m04309
  4. Bennabi D, Aouizerate B, El-Hage W, Doumy O, Moliere F, Courtet P, Nieto I, Bellivier F, Bubrovsky M, Vaiva G, Holztmann J. Risk factors for treatment resistance in unipolar depression: a systematic review. Journal of Affective Disorders. 2015 Jan 15;171:137-41. https://doi.org/10.1016/j.jad.2014.09.020
  5. El Hage W, Leman S, Camus V, Belzung C. Mechanisms of antidepressant resistance. Frontiers in Pharmacology. 2013 Nov 22;4:146. https://doi.org/10.3389/fphar.2013.00146
  6. Willner P, Scheel-Krüger J, Belzung C. Resistance to antidepressant drugs: the case for a more predisposition-based and less hippocampocentric research paradigm. Behavioural Pharmacology. 2014 Sep 1;25(5 and 6):352- 71. https://doi.org/10.1097/fbp.0000000000000066
  7. Pariante CM. Depression, stress and the adrenal axis. Journal of Neuroendocrinology. 2003 Aug;15(8):811-2.   
  8. Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. The British Journal of Psychiatry. 2009 Apr;194(4):342-9. https://doi.org/10.1192/bjp.bp.108.050278
  9. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology. 2013 Feb;38(3):377. https://doi.org/10.1038/npp.2012.191
  10. Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones DN, Drevets WC, Cowen PJ, Harrison NA, Pointon L, Pariante CM, Bullmore ET. Treatment-resistant depression and peripheral C-reactive protein. The British Journal of Psychiatry. 2018 May:1-9. https://doi.org/10.1101/197012
  11. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J, Gilbody S, Haddad PM. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2015 May;29(5):459-525. https://doi.org/10.1177/0269881115581093
  12. Taylor D, Barnes T, Young A. The Maudsley prescribing guidelines in psychiatry. 13th ed. Chichester, West Sussex: Wiley-Blackwell; 2018.            
  13. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Washington, D.C.: American Psychiatric Association; 2010.
  14. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Unipolar Depressive Disorders, Bauer M, Bschor T, Pfennig A. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. The World Journal of Biological Psychiatry. 2007 Jan 1;8(2):67-104. https://doi.org/10.1080/15622970701227829
  15. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. The Canadian Journal of Psychiatry. 2016 Sep;61(9):540-60. https://doi.org/10.1177/0706743716659417
  16. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. American Journal of Psychiatry. 2006 Nov;163(11):1905-17. https://doi.org/10.1176/ajp.2006.163.11.1905
  17. National Institute of Health and Care Excellence (NICE). Depression in adults: treatment and management: In development [GID-CGWAVE0725]. NICE;.
  18. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Current Medical Research and Opinion. 2017 Apr 3;33(4):701-11. https://doi.org/10.1080/03007995.2016.1277201
  19. Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018 Feb 1;75(2):139-48. https://doi.org/10.1001/jamapsychiatry.2017.3739
  20. Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H, Muskin PR, Brown RP, Mischoulon D. S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research. The Journal of Clinical Psychiatry. 2017 Jun;78(6):e656. https://doi.org/10.4088/jcp.16r11113
  21. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008 Feb 27;299(8):901-13. https://doi.org/10.1001/jama.299.8.901
  22. Barth J, Munder T, Gerger H, Nüesch E, Trelle S, Znoj H, Jüni P, Cuijpers P. Comparative Efficacy of Seven Psychotherapeutic Interventions for Patients with Depression: A Network Meta-Analysis. PLOS Medicine. 2013 May;10(5). https://doi.org/10.1371/journal.pmed.1001454
  23. Cusin C, Dougherty DD. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biology of Mood & Anxiety Disorders. 2012 Dec;2(1):14. https://doi.org/10.1186/2045-5380-2-14
  24. Kirov GG, Owen L, Ballard H, Leighton A, Hannigan K, Llewellyn D, Escott-Price V, Atkins M. Evaluation of cumulative cognitive deficits from electroconvulsive therapy. The British Journal of Psychiatry. 2016 Mar;208(3):266-70. https://doi.org/10.1192/bjp.bp.114.158261
  25. National Institute for Health and Care Excellence (NICE). Repetitive transcranial magnetic stimulation for depression: Interventional procedures guidance [IPG542]. NICE; 2015.    
  26. Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, Johnson CR, Seidman S, Giller C, Haines S, Simpson Jr RK. Vagus nerve stimulation (VNS™) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001 Nov 1;25(5):713-28. https://doi.org/10.1016/s0893-133x(01)00271-8
  27. Morishita T, Fayad SM, Higuchi MA, Nestor KA, Foote KD. Deep brain stimulation for treatment-resistant depression: systematic review of clinical outcomes. Neurotherapeutics. 2014 Jul 1;11(3):475-84. https://doi.org/10.1007/s13311-014-0282-1